Senhwa Biosciences, a clinical-stage biopharmaceutical company based in Taiwan, has entered a partnership with a global investment group to accelerate its artificial intelligence-related drug development. According to an April 14 report, Senhwa Biosciences has signed a Memorandum of Understanding (MOU)…
Related Posts
NFT sales show modest recovery, Pudgy Penguins jump 110%
After weeks of steep declines in participation, the NFT market is showing early signs of stabilization, buoyed by…
NVIDIA revenue hits $96.2B as AI demand doubles
NVIDIA reported $96.2 billion in Q2 revenue, beat Wall Street estimates and projected $108 billion for fiscal Q3.
Bitget, Floki teams accuse each other of manipulation after token listing
The teams for crypto exchange Bitget and Web3 protocol Floki blamed each other for allegedly misleading investors.